This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
One in five women suffer from hypertension worldwide, and almost half of the mortality in women is caused by cardiovascular disease (CVD) (WHO). The timely launch of the Women’s Health Strategy for England in 2022 focuses attention on the changing health and needs of women across their life.
Systematic search conducted without language restrictions from December 1, 2019 to June 31, 2022 on PubMed, EMBASE, Web of Science, Cochrane library, ProQuest Coronavirus Research Database, COVID-19 Living Overview of the Evidence (L-OVE) subset of Episteminokos and the World Health Organization (WHO) Covid-19 databases.
The BACKBEAT pivotal study will evaluate the efficacy and safety of atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT), for the treatment of pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications. Orchestra BioMed and Medtronic, Inc. Kowal, M.D., and Europe.
Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
ObjectiveTo explore the risk factors for cardiotoxicity in patients with gastrointestinal (GI) tumors treated with fluorouracil drugs.MethodsThis study included patients with GI tumors who received fluorouracil at our hospital between January 2018 and April 2022. The demographic and clinical characteristics were collected.
is at an all time high, with 942k cardiovascular disease-related deaths in 2022, up by 10k from 2021. as of 2020) have some form of CVD (comprising CHD, HF, stroke, and hypertension). Excluding hypertension (CHD, HF, and stroke only), just 9.9% Four years after that goals due date, the burden of CVD in the U.S. adults have CVD.
What is the impact on prognosis of the 2022 ESC/ERS pulmonary hypertension (PH) guidelines on the new redefined hemodynamic threshold for the diagnosis of precapillary PH?
Background Hypertension has now developed into a major public health problem worldwide. Objective This study aimed to systematically evaluate the effect of acupuncture alone or in combination with antihypertensive drugs on the efficiency of reducing blood pressure and controlling blood pressure in elderly patients with hypertension.
Background Pulmonary hypertension (PH) is linked to higher rates of morbidity and mortality worldwide. Methods In the retrospective study, patients admitted to our hospital between January 2022 and April 2023 were classified into PH and control groups using ePASP and compared with acoustic cardiographic parameters.
Objectives The association of pulmonary hypertension (PH) with the outcome after mitral transcatheter edge-to-edge repair (M-TEER) focusing on the new ESC/ERS guidelines definition for PH. to 2.07); p<0.001 and 2022: HR 2.09 (95% CI 1.54 to 2.83); p<0.001).
For more information: www.honorhealth.com Related content: Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients Orchestra BioMed Announces (..)
Hypertension, Ahead of Print. Among individuals with HDP, we evaluated the association between race, ethnicity, and other socioeconomic factors and (1) postpartum visit attendance and (2) postpartum counseling/screening.RESULTS:Among 42 858 participants with HDP (weighted n=2 011 284), 90% reported attending a postpartum visit.
The AAMR declined from 1999 to 2016 (APC -3.0 [-3.3, -2.8]) and rose till 2022 (APC 4.6 [3.4, 17.9]) and NH American Indian or Alaska Native men (1999-2022, APC (-0.6 [-1.6, to 2022, respectively, after an initial decline. to 2022, respectively, after an initial decline. 100000 people). 100000 people).
This new document builds off of the previously published Best Practices for Consumer Cardiovascular Technology Solutions in January 2022. The framework outlines opportunities for the broader integration of the technology into the workflow for screening and diagnosing cardiovascular disease, using AFib and Hypertension as examples.
BACKGROUND:The focus for reducing hypertension-related cardiovascular disease is the management of blood pressure. Participants were stratified by duration of recognized hypertension: normotensive (0 years), 5 years, 6 to 20 years, or 21+ years. Stroke, Volume 56, Issue 1 , Page 105-112, January 1, 2025. mm Hg (95% CI, 132.0133.1).
Aim:To examine factors associated with achieving the recommended weekly minimum of 150 minutes of moderate-intensity physical activity among wearable device users.Methods:Data from the 2022 Health Information National Trends Survey (HINTS 6) of wearable device users (n = 1,718) were analyzed. were female with a mean (M) age of 48.2 ± 0.36
Background Hypertension is a silent killer that causes serious health issues in all parts of the world. Self-monitoring practice has been identified as an important component of hypertension management. to 18.58)) and knowledge on hypertension self-care (AOR 13.13, 95% CI (4.21 and then exported to SPSS V.25
What is the impact and prognostic value of the new 2022 European guideline definition of post-capillary pulmonary hypertension (pcPH) in heart failure (HF), which lowered the level of mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR)?
The aim was to explore the effect of irbesartan combining with emodin on myocardial remodeling in goldblatt (2K-1C) hypertensive rats. Conclusions: Irbesartan or Emodin or two drugs together can inhibit myocardial remodeling in renovascular hypertension rats probably by reducing TGF-β1 and CTGF expression. Correspondence to: Prof.
Hypertension and obesity were defined using AHA and CDC guidelines. We used logistic regression to estimate the odds of hypertension and obesity among family types adjusted for age and gender and assessed nativity modification using an interaction term.Results:Among 147 Hispanic adults, 56.0% had hypertension, 58.2% had obesity.
Phase II and III randomized clinical trials were identified by searching the MEDLINE/PubMed, Cochrane Library and ASCO Meeting abstracts, from inception to June 2022. 1.53), but no significant difference was found for any-grade hypertension, and for vascular events. 2.97) and PFS (HR 0.49, 95% CI: 0.39–0.63)
Annual inflation-adjusted (2022 US dollars) health care costs of cardiovascular risk factors are projected to triple between 2020 and 2050, from $400 billion to $1344 billion.
Introduction:The demographics of patients with pulmonary arterial hypertension (PAH) is shifting towards older age, increased comorbidity burden, and an increase in the risk of left ventricular (LV) diastolic dysfunction. 2022 were included. Circulation, Volume 150, Issue Suppl_1 , Page A4146852-A4146852, November 12, 2024.
IntroductionThe efficacy of blood pressure (BP) reduction of Sacubitril/valsartan has been proved in hypertension patients, yet not in patients with acute ischemic stroke (AIS).
BackgroundPulmonary hypertension (PH) is highly prevalent in patients with heart failure with preserved ejection fraction (HFpEF), and it is a strong predictor of adverse outcomes. Journal of the American Heart Association, Ahead of Print.
BACKGROUND:Remote health management programs utilizing evidence-based algorithm-driven virtual care solutions for chronic disease management offer a novel approach to addressing implementation gaps for conditions such as hypertension. Most patient participants were male (n=12) and identified their race and ethnicity as White (n=15).
A 50-something male with hypertension and 20- to 40-year smoking history presented with 1 week of stuttering chest pain that is worse with exertion, which takes many minutes to resolve after resting and never occurs at rest. It is a ssociated with mild dyspnea on exertion. At times the pain does go to his left neck.
Retrieved July 2, 2022, from [link] Moyé, D. Retrieved July 2, 2022, from [link] Sybrandy, K. Retrieved July 2, 2022, from [link] == MY Comment , by K EN G RAUER, MD ( 2/4 /2024 ): == Today's case by Dr. Small-but-present initial Q waves are seen in 4/6 chest leads ( ie, in leads V2,V3,V4,V5 — as per the RED arrows in Figure-1 ).
MY Comment, by K EN G RAUER, MD ( 12/10 /2022 ): == Sometimes an ECG raises more questions than it answers! It takes expertise to find the distinction. Syncope without chest discomfort has a very low pretest probability 4. It is no crime to have a false positive cath lab activation.
Methods Data were obtained from the electronic medical records of all adult patients at three hospitals between 1 January 2018, and 31 December 2022. Hyperlipidemia, hypertension, age, vegetation size (>10 mm), S. Two predictive models, logistic regression and BN, were used. Results A total of 542 patients [mean (SD) age, 49.6
Hypertension, Volume 80, Issue 12 , Page 2523-2532, December 1, 2023. In 2022, Target: BP™ recognized 1309 health care organizations serving 8.4 million patients with hypertension for prioritizing BP control, 675 of which affirmed performance of evidence-based BP measurement activities and 551 of which reported BP control rates ≥70%.
In patients with associated supine hypertension, the criteria for orthostatic hypotension allows for a drop of at least 30 mm Hg in SBP or 15 mm Hg in DBP. Jordan J, Consensus statement on the definition of orthostatic hypertension endorsed by the American Autonomic Society and the Japanese Society of Hypertension. Hypertension.
Subscribe now 1 Hypertensive therapy: attacking the renin-angiotensin system. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. 2022 Nov 1;7(11):1138-1146. If it’s not in the low 120s systolic range or below, think about what that might mean for you and what you need to do to get there.
Hypertension, Ahead of Print. BACKGROUND:Primary aldosteronism (PA) is a common but underdiagnosed cause of hypertension. We distributed the survey through academic medical centers, Amazon Mechanical Turk, Twitter, PA patient advocacy groups, and hypertension support groups on Facebook between March 21 and June 5, 2022.RESULTS:Of
The pipeline of algorithms likely to clear regulatory hurdles and enter the cardiac market over the next 12-18 months include those for Pulmonary Hypertension, Cardiac Amyloidosis, Diastolic dysfunction, and Hyperkalaemia. In April 2022 BMS had received FDA approval for Camzyos, the first drug developed specifically for targeting HCM.
2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 4 Approximately 6.7
Background:The STRACK project aims to improve post-stroke patient management and the transition from acute to primary care thanks to improvements in patient pathways and monitoring cardiovascular risk factors: heart failure, diabetes, atrial fibrillation, dyslipidemia and hypertension.
Written by Willy Frick with edits by Ken Grauer A woman in her 70s with a history of hypertension presented with acute onset shortness of breath. More than just RBBB — the qR pattern in lead V1 is an ECG indicator of pulmonary hypertension in today's case ( See My Comment in the March 28, 2022 post in Dr. Smith's ECG Blog ).
Introduction Hypertension is the leading modifiable risk factor for cardiovascular disease and is implicated in half of all strokes and myocardial infarctions. One-third of the adults in Scotland have hypertension yet only a quarter of them have their blood pressure (BP) controlled to target (<140/90 mm Hg).
Results Forty participants were recruited between 15 March 2021 and 19 July 2022. 33% of participants had a new finding of hypertension. 33% of participants had a new finding of hypertension. Participants underwent clinical cardiovascular evaluation, ECG, cardiac biomarker evaluation and CMR. years (range 5.9–10.8
The study is the largest and most robust of its kind to date, examining 102,475 Hello Heart users with high BP (hypertension) between January 2018 and December 2022. Users were equipped with Hello Heart’s connected heart health monitor and mobile app with digital coaching. of their body weight.
Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry. 2022 Apr 23;15:857-867. They are not wrong statements for sure. It only reflects the complexity of the interaction of PIH with PPCM. The reference 70 & 71 is linked below 70.Jackson Jackson AM, Petrie MC, Frogoudaki A, et al.
Hypertension, Ahead of Print. Background:Preeclampsia, a pregnancy-specific condition associated with new-onset hypertension after 20-week gestation, is a leading cause of maternal and neonatal morbidity and mortality.
Methods From November 2022 to May 2024, we conducted an outpatient follow-up of 41 patients receiving WCD. Among the cohort, 54% had hypertension, 41% were smokers and 66% had dyslipidaemia, while 27% were diabetic. Regular check-ups, remote monitoring and comprehensive echocardiography were performed to optimise a tailored therapy.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content